Literature DB >> 17576985

Advances in the medical management of benign prostatic hyperplasia.

Michael A S Jewett1, Laurence H Klotz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576985      PMCID： PMC1891132          DOI： 10.1503/cmaj.060439

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

2.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

Authors:  W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

3.  Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

Authors:  C G Roehrborn; P Boyle; D Bergner; T Gray; M Gittelman; T Shown; A Melman; R B Bracken; R deVere White; A Taylor; D Wang; J Waldstreicher
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

4.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

5.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Authors:  Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

6.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
  6 in total
  1 in total

1.  Finasteride therapy for benign prostatic hyperplasia.

Authors:  Thomas J Helling
Journal:  CMAJ       Date:  2008-02-26       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.